December 1989 in “Inpharma (Balgowlah)” Cyproterone helps women with hair loss caused by genetics. More research is needed to confirm the best dose.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
14 citations
,
October 2016 in “Physiological Research” Alfacalcidiol and metformin together lowered testosterone in women with PCOS, but did not significantly improve acne, hair growth, or pregnancy rates.
26 citations
,
April 2023 in “Medicina” Platelet-rich plasma therapy improves oral lichen planus symptoms with few side effects.
68 citations
,
May 1991 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Both cyproterone acetate and spironolactone effectively reduce hair growth in women with hirsutism.
2 citations
,
January 2023 in “Skin Appendage Disorders” Hydroxychloroquine may help some hair disorders, but results vary.
2 citations
,
July 2021 in “Journal of Cardiovascular Pharmacology” Lisinopril improves heart health more in men with normal hair than those with early hair loss.
September 2022 in “Research Square (Research Square)” Probiotics and synbiotics may help with PCOS symptoms, but more research is needed.
1 citations
,
May 2025 in “Journal of the Indian Chemical Society” 1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
Researchers made new compounds that could potentially be developed into anticancer drugs.
10 citations
,
June 2018 in “Aaps Pharmscitech” The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
13 citations
,
July 2003 in “Annals of the Rheumatic Diseases” Co-trimoxazole successfully treated a girl with multiple autoimmune symptoms.
February 2024 in “Future science OA” Loss of the Y chromosome and UTY gene activity increases cancer risk in men.
April 2023 in “Medicina Clínica (english Edition)”
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
4 citations
,
July 1987 in “Dermatologic Clinics”
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
January 2017 in “ScholarWorks - WMU (Western Michigan University)” Stopping SSRIs can reverse hair loss in some patients.
3 citations
,
October 2011 in “JAT. Journal of applied toxicology/Journal of applied toxicology” Doxazosin mesylate and saw palmetto cause genetic changes in fruit flies.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
May 2023 in “Zenodo (CERN European Organization for Nuclear Research)”
105 citations
,
December 2009 in “Archives of dermatology” A specific drug can help treat Lichen Planopilaris, a condition causing permanent hair loss.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
16 citations
,
November 2020 in “Research Square (Research Square)” Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.
40 citations
,
January 2017 in “Intestinal Research” Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.
September 2018 in “Practical diabetes” Sodium valproate is not recommended as a first-line treatment for neuropathy but may be used in resistant cases.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.